文献速递类风湿关节炎

超声-临床关节炎活动度(US-CLARA)指数:一种新的类风湿关节炎复合疾病活动度指数的特性

The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2017-09-28

本研究在开始阿巴西普(abatacept)治疗的类风湿关节炎(RA)患者中评估US-CLARA指数的有效性、反应性和可解释性。130例患者完成6个月随访,US-CLARA与DAS28-CRP、DAS28-ESR呈中度相关,与SDAI、CDAI相关性更高;内部反应性SRM和ES为0.91至1.51,与DAS28、SDAI、CDAI相似;并确定了针对SDAI缓解、低、中、高疾病活动度的 cutoff 值。结论认为US-CLARA是评估RA疾病活动度的有效且敏感的工具。

要点

  • US-CLARA与DAS28-CRP及DAS28-ESR呈中度相关,与SDAI和CDAI相关性更高。
  • US-CLARA内部反应性SRM和ES为0.91至1.51,与DAS28、SDAI、CDAI相似。
  • US-CLARA cutoff值:缓解<2.0,低活动度2.0≤US-CLARA<3,中活动度3≤US-CLARA≤4.8,高活动度>4.8。

核心结论

  • US-CLARA是评估类风湿关节炎疾病活动度的有效且敏感的工具。

研究设计与样本

  • 纵向研究,纳入开始阿巴西普治疗的类风湿关节炎患者,在前6个月治疗期间进行三次访视并完成综合临床计量学评估。
  • 共130例患者完成研究。

主要发现

  • US-CLARA与DAS28-CRP及DAS28-ESR呈中度相关,与SDAI和CDAI评分相关性更高。
  • 内部反应性宽,SRM和ES范围为0.91至1.51;US-CLARA的反应性与DAS28、SDAI或CDAI相似。
  • US-CLARA的ROC曲线下面积(AUC-ROC)给出相同结果;6个月随访期间计算的所有组合的累积炎症负荷AUC高度相关(p < 0.0001)。

关键数值与推荐

  • 缓解(REM)的cutoff值:US-CLARA <2.0。
  • 低疾病活动度(LDA)的cutoff值:2.0 ≤US-CLARA <3。
  • 中疾病活动度(MDA)的cutoff值:3 ≤US-CLARA ≤4.8。
  • 高疾病活动度(HDA)的cutoff值:US-CLARA >4.8。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess validity, responsiveness and interpretability of the UltraSound-CLinical ARthritis Activity (US-CLARA) index in patients with rheumatoid arthritis (RA). METHODS: In this longitudinal study were involved RA patients starting treatment with abatacept. Subjects were followed along three visits in the first 6 months of therapy and underwent a comprehensive clinimetric evaluation. Validity was explored correlating the baseline scores and the cumulative inflammatory burden of the US-CLARA with the other composite indices applied. Sensitivity to change was assessed after 6 months of treatment in terms of internal and external responsiveness. Interpretability was defined in terms of determination of cutoffs against external criteria for remission (REM), low disease activity (LDA), moderate disease activity (MDA), and high disease activity (HDA) of SDAI. RESULTS: One-hundred and thirty patients completed the study. VALIDITY: moderate correlations were observed between US-CLARA and both DAS28-CRP and DAS28-ESR. Higher correlations were also found between US-CLARA and both SDAI and CDAI scores. Responsiveness: internal responsiveness was wide, with SRM and ES ranging from 0.91 to 1.51. US-CLARA responsiveness was similar to that of DAS28, SDAI, or CDAI. Similarly, the area under ROC curve (AUC-ROC) of US-CLARA gives identical results. The AUC of cumulative inflammatory burden, calculated during the 6-months follow-up of all combinations were highly correlated (p < 0.0001). Interpretability: cutoff values for REM, US-CLARA <2.0; for LDA, 2.0 ≤US-CLARA <3; for MDA, 3 ≤US-CLARA ≤4.8; for HDA, US-CLARA >4.8. CONCLUSION: The US-CLARA is valid and sensitive tool to assess disease activity in RA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Salaffi F, Di Carlo M, Iannone F, et al. The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. Semin Arthritis Rheum. 2017. PMID: 29102157. doi:10.1016/j.semarthrit.2017.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。